Hypercoagulability in multiple myeloma

Terapevticheskii Arkhiv

Volumn 86, Issue 7, 2014, Pages 73-79

  Urnova, E S ^a   Pokrovskaya, O S ^a   Gracheva, M A ^a   Vasilyev, S A ^a   Gemdjian, E G ^a   Tarandovsky, I D ^a   Mendeleeva, L P ^a  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

D dimer; Hypercoagulability; Multiple myeloma; Multivariate analysis; Prospective study; Thombodynamics; Thrombin generation test; Thromboses

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; HEPARIN;

ADULT; AGED; ARTICLE; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HEMOSTASIS; HUMAN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDY; SYNDROME; THROMBOPHILIA; TREATMENT OUTCOME;

ADULT; AGED; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPIRIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOSTASIS; HEPARIN; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SYNDROME; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 84908147230     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Palumbo A., Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-1060.
2. Coppola A., Tufano A., Capua U. D., Franchini M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 2011;37:929-945.
3. Barlogie B., Tricot G., Anaissie E. et al. Thalidomide and hematopoetic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-1030.
4. Baz R., Li L., Kottke-Marchant K. et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005;80:1568-1574.
5. Palumbo A., Rajkumar S. V., Dimopoulos MA. et al. Prevention of thalidomide- and lenolidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-423.
6. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009;145:151-163.
7. Zangary M., Elice F., Fink L., Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther 2007;7(3):307-315.
8. Aurwerda J. J., Yuana Y., Osanto S. et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thrombos Haemostas 2011:105(1):14-20.
9. Zangari M., Bemo T., Zhan F. Mechanisms of Thrombosis in paraproteinemias: the effects of Immunomodulatory drugs. Semin Thromb Hemost 2012;38:768-779.
10. Zangary M., Elice F., Fink L., Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther 2007;7(3):307-315.
11. Elice F., Fink L., Tricot G. et al. Acquired resistence to activated protein C (aAPRC) in multiple myeloma is transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006;134:399-405.
12. Auwerda J. J., Sonneveld P., De Maat M. P., Leebeek F. W. Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders. Clin Lymphoma Myeloma 2007;7(7):462-466.
13. Krisyinson S. Y. Thrombosis in multiple myeloma. Hematology 2010:12:437-444.
14. Krisyin Kanis JA., Ms Closkey E. V. The use of clodronate in disorders of calcium and skeletal metabolism. Prog Basic Clin Pharmacol 1990;4:89-136.
15. Libourel E. J., Sonneveld P., Van Der Holt B. et al. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a progressive cohort study. Blood 2010;116(1):22-26.
16. Palumbo A., Rajkumar S. V., Dimopoulos MA. et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Intern Myeloma Working Group Leukemia 2008;22(2):414-423.
17. Loinal S., Richardson P. G., San Miguel J. et al. Characterisation of haematological profiles and low risk of thrombotic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 2008;143(2):222-229.
18. Hemker H. C., Begum S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995;74(5):134-138.